Compare
Soliris vs. Ultomiris

Soliris (eculizumab) is used to treat certain nerve problems, such as myasthenia gravis. It can also help with rare blood problems, like paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. This medication is a monoclonal antibody known as a complement inhibitor. It's given as an infusion through the vein by a healthcare professional. Side effects include headache, nausea, and high blood pressure. There's also a risk of serious meningococcal infection. So, it's only available through a special program called the Soliris Risk Evaluation and Mitigation Strategy (REMS). Currenly, Soliris (eculizumab) is a brand-name medication only.

• Paroxysmal nocturnal hemoglobinuria (PNH) in adults
• Atypical hemolytic uremic syndrome (aHUS) in adults and children
• Generalized myasthenia gravis (gMG) in certain people who are 6 years and older
• Neuromyelitis optica spectrum disorder (NMOSD)) in certain adults

PNH:

• Headache (44%)
• Cold-like symptoms (23%)
• Back pain (19%)
• Nausea (16%)
• Tiredness (12%)
• Cough (12%)

aHUS:

• Headache (41%)
• Diarrhea (37%)
• Vomiting (30%)
• High blood pressure (33%)
• Cold-like symptoms (27%)
• Anemia (26%)
• Nausea (23%)
• Swelling in the arms or legs (23%)
• Cough (23%)
• Urinary tract infection (22%)
• Fever (21%)

gMG:

• Headache (26%)
• Cold-like symptoms (24%)
• Diarrhea (15%)
• Joint pain (12%)
• Upper respiratory tract infection (11%)
• Nausea (10%)

NMOSD:

• Upper respiratory tract infection (29%)
• Cold-like symptoms (21%)
• Diarrhea (16%)
• Dizziness (15%)
• Back pain (15%)
• Joint pain (11%)
• Flu (11%)
• Sore throat (10%)
• Bruising (10%)

• Risk of serious meningococcal infections
• Risk of other serious infections
• Worsening of PNH after stopping treatment
• Worsening of aHUS after stopping treatment
• Infusion reactions

Ultomiris (ravulizumab or ravulizumab-cwvz) is a type of monoclonal antibody called a complement inhibitor. This medication is used to treat adults and children with certain autoimmune conditions that affect the blood or nerves. It's given as an infusion through the veins (IV) once every 1 or 2 months. For certain adults, the medication can also be injected under the skin (subcutaneous) once per week. Side effects include upper respiratory tract infections and headache. Ultomiris (ravulizumab) is available only through the FDA’s Ultomiris REMS program because of the risk for serious meningococcal infections.

• Paroxysmal nocturnal hemoglobinuria (PNH) in adults and children ages 1 month and older
• Atypical hemolytic uremic syndrome (aHUS) in adults and children ages 1 month and older
• Generalized myasthenia gravis (gMG) in adults
• Neuromyelitis optica spectrum disorder (NMOSD) in adults

PNH: Note: Side effects reported by adults with PNH getting IV infusions of Ultomiris (ravulizumab)

• Upper respiratory tract infection (39%)
• Headache (32%)

aHUS:

• Headache (40%)
• Diarrhea (31%)
• Nausea (26%)
• Vomiting (26%)
• Upper respiratory tract infection (26%)
• High blood pressure (24%)
• Joint pain (22%)
• Fever (19%)
• Cough (17%)
• Shortness of breath (17%)
• Swelling in arms or legs (17%)
• Urinary tract infection (17%)

gMG:

• Diarrhea (15%)
• Upper respiratory tract infection (14%)

NMOSD:

• COVID-19 infection (24%)
• Headache (24%)
• Back pain (12%)
• Joint pain (10%)
• Urinary tract infection (10%)

• Serious infections (especially meningococcal infections)
• Problems that happen after you stop treatment - for people with PNH or aHUS only
• Infusion-related reactions and allergic reactions
• Allergy to acrylic adhesives - for Ultomiris (ravulizumab) on-body injector only